Immunicum announces corporate rebranding and name change to Mendus AB. The rebranding reflects an advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations, states the
Nordic Life Science
Pharma news from the Nordic life science industry
Latest news
The company has entered into a binding agreement for a financing commitment with Negma Group (of up to 200 MSEK) as well as a binding commitment letter to receive a
The Board has initiated this review aiming to optimize shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin and implement a restructuring
Oncopeptides has announced that the European Commission has granted Pepaxti marketing authorization in combination with dexamethasone. The approval concerns the treatment of adult patients with multiple myeloma who have received
Idogen has announced that an Extraordinary General Shareholder Meeting will be convened to propose the election of two new members to the Board of Directors: Joakim Söderström and Niklas Wallett,
Private equity fund EQT has made a cash offer for the remaining shares in Swedish biopharmaceuticals group Karo Pharma. EQT currently owns 86% of Karo Pharma. The total value of
Earlier this summer the company won the Life Science Business Award of the city (Malmö Näringslivspris Life Science). The jury stressed the important role of PolyPeptide as part of Malmö’s
The pharma giant has completed the acquisition of TeneoTwo (announced July 5 2022), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) darolutamide in
Zealand Pharma has given formal notice to Nasdaq of the company’s intention to voluntarily remove its American Depositary Shares (ADSs) from listing on the New York-based Nasdaq Global Select Market.
Clinical trials
Ultimovacs has announced positive 2-year overall survival data in its ongoing phase I clinical study of the cancer vaccine UV1 in combination with pembrolizumab for the treatment of malignant melanoma.
The Clinical Trial Application (CTA) to initiate the company’s Phase 2b study, with its candidate drug, AP1189, in patients with newly diagnosed rheumatoid arthritis (RA) has been approved in Moldova.
During the summer, the application to start clinical studies of PN6047 was approved by the Swedish Medical Products Agency and Ethical Review Authority, and the first dose has now been
Ultimovacs has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to
The company’s Phase 1 clinical safety study on the drug candidate AQ280 on healthy volunteers has started. The substance AQ280, part of the company’s Regulus development program, is a super
Isofol Medical has announced that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center,
BioInvent International has announced treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors. The first-in-human
Mendus has announced the publication of in vivo data demonstrating significant anti-tumor synergies between the company’s allogeneic dendritic cell-based immune primer program ilixadencel and immune checkpoint inhibition via CTLA-4 blockade
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation
Sustainability
A new study by an international consortium, including researchers from Stockholm University, looking at the presence of pharmaceuticals in the world’s rivers, found concentrations at potentially toxic levels in more
The manifesto, launched by the trade association for the research-based pharmaceutical industry in Sweden (Lif), includes nine commitments that covers the entire value chain of medicines, from research and development
The professorship at the University of Helsinki, which is being established with the support of a fund, is aimed at strengthening sustainable development expertise in pharmacy across the globe. The
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain
Sign up to our newsletter
[mc4wp_form id="id=``11984``"]